)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Evommune
Evommune (EVMN) investor relations material
Evommune Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Pipeline includes EVO301 and EVO756 clinical programs, plus preclinical EVO646 and licensed EVO570; EVO756 development in CSU and AD was discontinued after Phase 2b trials missed primary endpoints, while migraine development continues.
EVO301 Phase 2a AD results showed a 55% EASI reduction at Week 12 versus 22% on placebo (p<0.01), with responses deepening during follow-up; treatment was well tolerated.
EVO570 licensing broadened the pipeline; several clinical and data milestones are planned for 2027.
Cash, cash equivalents and investments of $262.3M support anticipated runway into H2 2029.
Financial highlights
Q3 2026 revenue was $0 versus $10.0M in Q3 2025; 9M revenue was $0 versus $13.0M, all from prior-year Maruho license revenue.
Q3 operating expenses were $33.3M and net loss was $30.9M, versus $23.3M and $12.5M; 9M expenses were $92.2M and net loss was $84.8M.
Q3 R&D was $24.6M versus $19.6M; 9M R&D was $68.3M versus $53.6M. Q3 G&A was $8.8M versus $3.7M; 9M G&A was $23.9M versus $10.7M.
9M expense increases reflected discovery research, personnel, stock compensation and public-company costs.
Outlook and guidance
EVO756 migraine Phase 2b enrollment began in July 2026, with initial results expected in H2 2027; EVO301 UC Phase 2 is planned for Q1 2027, with data expected in 2028.
EVO301 global Phase 2b AD trial is expected to start in mid-2027; plans include three dose regimens versus placebo, 16 weeks of dosing and follow-up through Week 24.
EVO570 Phase 1 is expected in Q1 2027, with healthy-volunteer and biomarker data targeted for mid-2027; Phase 2 in rheumatoid arthritis is planned for 2H 2027.
EVO646 Phase 1 is planned for H1 2027, with healthy-volunteer and biomarker data expected in 2H 2027; EVO756 migraine top-line data are expected in H2 2027.
Current-plan cash runway is expected into H2 2029; a $5.0M Maruho milestone triggered by October completion of the EVO756 CSU study is expected to be recognized as Q4 2026 revenue.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Evommune
- EVO301 advances after positive AD Phase 2a results, with four programs moving toward key trials.EVMN
Corporate presentation - 2027 brings key readouts across IL-18, TLR7/8, VAV1 and migraine programs.EVMNStifel 2026 Healthcare Conference 2026
- EVO570 advances toward RA phase II, with phase I data expected mid-2027.EVMNInvestor update
- Three immunology programs advance toward key clinical milestones through 2027–2028.EVMNCorporate presentation
- EVO570 pairs potent VAV1 degradation with a planned 2027 RA proof-of-concept path.EVMNCompany presentation
- Advancing IL-18 and MRGPRX2 programs with strong funding and AI-driven innovation.EVMNMorgan Stanley 24th Annual Global Healthcare Conference
- Innovative therapies for inflammation, migraine, and autoimmunity advance toward late-stage trials.EVMNCorporate presentation
- Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum.EVMNCorporate presentation
- Net loss rose to $53.9 million as expenses increased, but cash runway extends through 2028.EVMNQ2 2026
Next Evommune earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
Evommune
Next Evommune earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)